Diergaarde Brenda, Kurta Michelle L
aDepartment of Epidemiology, Graduate School of Public Health, University of Pittsburgh, and University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania bThe Ohio State University Comprehensive Cancer Center, Columbus, Ohio, USA.
Curr Opin Obstet Gynecol. 2014 Jun;26(3):125-9. doi: 10.1097/GCO.0000000000000060.
The purpose of this review is to highlight recent research and insights into the relationship between fertility drug use and ovarian cancer risk.
Results from two large case-control studies provided further evidence that fertility drug use does not significantly contribute to risk of ovarian cancer among the majority of women when adjusting for known confounding factors. However, questions regarding the effect on certain subgroups, including long-term fertility drug users, women who remain nulligravid after fertility treatment, women with BRCA1 or BRCA2 mutations and borderline ovarian tumours, still remain. In addition, it may currently just be too early to determine whether there is an association between fertility drug use and ovarian cancer risk given that many of the exposed women are only now beginning to reach the ovarian cancer age range.
Whether use of fertility drugs increases the risk of ovarian cancer is an important question that requires further investigation, in particular given the large number of women utilizing fertility treatments. Fortunately, results from recent studies have been mainly reassuring. Large well designed studies with sufficient follow-up time are needed to further evaluate the effects of fertility treatments within subgroups defined by patient and tumour characteristics.
本综述旨在强调近期关于生育药物使用与卵巢癌风险之间关系的研究及见解。
两项大型病例对照研究结果进一步证明，在调整已知混杂因素后，生育药物的使用对大多数女性患卵巢癌的风险没有显著影响。然而，关于生育药物对某些亚组的影响，包括长期使用生育药物的女性、生育治疗后仍未孕的女性、携带BRCA1或BRCA2突变的女性以及卵巢交界性肿瘤患者，仍存在疑问。此外，鉴于许多暴露于生育药物的女性才刚刚开始进入卵巢癌发病年龄范围，目前确定生育药物使用与卵巢癌风险之间是否存在关联可能还为时过早。
生育药物的使用是否会增加卵巢癌风险是一个需要进一步研究的重要问题，特别是考虑到大量使用生育治疗的女性。幸运的是，近期研究结果大多令人安心。需要进行设计良好且有足够随访时间的大型研究，以进一步评估在根据患者和肿瘤特征定义的亚组中生育治疗的效果。
